Ann M. Decker

Ann M. Decker

Auto-generated profile, based on publicly available information

Ann M. Decker

RTI International

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2017 in Neuropharmacology
Verified
Journal Article
Open access
FMFelix P Mayer
Felix P Mayer
NBNadine V. Burchardt
Nadine V. Burchardt
ADAnn M. Decker
Ann M. Decker
JPJohn S. Partilla
John S. Partilla
YLYang Li
Yang Li
HSHarald H. Sitte
Harald H. Sitte
A variety of new psychoactive substances (NPS) are appearing in recreational drug markets worldwide. NPS are compounds that target various receptors and transporters in the central nervous system to achieve their psychoactive effects. Chemical modifications of existing drugs can generate NPS that are not controlled by current legislation, thereby providing legal alternatives to controlled substances such as cocaine or amphetamine. Recently, 3-fluorophenmetrazine (3-FPM), a derivative of the anorectic compound phenmetrazine, appeared on the recreational drug market and adverse clinical effects have been reported. Phenmetrazine is known to elevate extracellular monoamine concentrations by an amphetamine-like mechanism. Here we tested 3-FPM and its positional isomers, 2-FPM and 4-FPM, for their abilities to interact with plasma membrane monoamine transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). We found that 2-, 3- and 4-FPM inhibit uptake mediated by DAT and NET in HEK293 cells with potencies comparable to cocaine (IC50 values < 2.5 μM), but display less potent effects at SERT (IC50 values >80 μM). Experiments directed at identifying transporter-mediated reverse transport revealed that FPM isomers induce efflux via DAT, NET and SERT in HEK293 cells, and this effect is augmented by the Na+/H+ ionophore monensin. Each FPM evoked concentration-dependent release of monoamines from rat brain synaptosomes. Hence, this study reports for the first time the mode of action for 2-, 3- and 4-FPM and identifies these NPS as monoamine releasers with marked potency at catecholamine transporters implicated in abuse and addiction. This article is part of the Special Issue entitled 'Designer Drugs and Legal Highs.'

7 February 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Md Toufiqur RahmanMd Toufiqur Rahman
Md Toufiqur Rahman
ADAnn M. Decker
Ann M. Decker
SHSami Ben Hamida
Sami Ben Hamida
DPDavid A. Perrey
David A. Perrey
HLHetti Handi Chaminda Lakmal
Hetti Handi Chaminda Lakmal
CJChunyang Jin
Chunyang Jin

12 May 2021 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
TNThuy Nguyen
Thuy Nguyen
TGThomas F. Gamage
Thomas F. Gamage
ADAnn M. Decker
Ann M. Decker
DFDavid B. Finlay
David B. Finlay
TLTiffany L. Langston
Tiffany L. Langston
YZYanan Zhang
Yanan Zhang

24 March 2022 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
ADAnn M. Decker
Ann M. Decker
MBMarcus F. Brackeen
Marcus F. Brackeen
AMAida Mohammadkhani
Aida Mohammadkhani
CKChad M. Kormos
Chad M. Kormos
DHDavid Hesk
David Hesk
BBBruce E. Blough
Bruce E. Blough

27 March 2017 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
ADAnn M. Decker
Ann M. Decker
EGElaine A. Gay
Elaine A. Gay
KMKelly M. Mathews
Kelly M. Mathews
TRTaylor C. Rosa
Taylor C. Rosa
TLTiffany L. Langston
Tiffany L. Langston
CJChunyang Jin
Chunyang Jin
GPR88 is an orphan G protein-coupled receptor highly expressed in the striatum and is implicated in basal ganglia-associated disorders. However, the receptor functions of GPR88 are still largely unknown due to the lack of potent and selective ligands appropriate for central nervous system investigation. Development of a high-throughput screening assay for GPR88 should facilitate the discovery of novel ligands to probe GPR88 functions. In this paper, we describe the development of a CHO-Gαqi5-GPR88 cell-based calcium mobilization assay. The assay takes advantage of functional coupling of GPR88 with the promiscuous Gαqi5 protein and consequent mobilization of intracellular calcium, which can be measured in a 384-well format with a Fluorescent Imaging Plate Reader. The CHO-Gαqi5-GPR88 cell-based calcium mobilization assay was validated by the structure-activity relationship study of known GPR88 agonist (1R,2R)-2-PCCA analogues. The assay was automated and miniaturized to a 384-well format, and was deemed robust and reproducible with a Z’-factor of 0.72 and tolerated dimethyl sulfoxide to a final concentration of 2%. Screening a pilot neurotransmitter library consisting of 228 compounds yielded 10 hits, but none of the hits were confirmed as GPR88 agonists in follow-up assays. We have developed a high-throughput calcium mobilization assay for the orphan receptor GPR88. This calcium mobilization assay can be used to identify several different types of GPR88 ligands including agonists, competitive and noncompetitive antagonists, inverse agonists, and allosteric modulators. These ligands will serve as valuable tools to probe signaling mechanisms and in vivo functions of GPR88, and could expedite development of novel therapies for diseases potentially mediated by GPR88.

20 December 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TNThuy Nguyen
Thuy Nguyen
TGThomas F. Gamage
Thomas F. Gamage
DFDavid Finlay
David Finlay
ADAnn M. Decker
Ann M. Decker
TLTiffany L. Langston
Tiffany L. Langston
YZYanan Zhang
Yanan Zhang